Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Low VWF levels in children and lack of association with bleeding in children undergoing tonsillectomy.

Gill JC, Conley SF, Johnson VP, Christopherson PA, Haberichter SL, Diaz CD, Strong TC, Zhang J, Simpson P, Abshire TC, Montgomery RR, Flood VH.

Blood Adv. 2020 Jan 14;4(1):100-105. doi: 10.1182/bloodadvances.2019000992.

2.

Factor VIII prophylaxis effects outweigh other hemostasis contributors in predicting severe haemophilia A joint outcomes.

Warren BB, Jacobson L, Kempton C, Buchanan GR, Recht M, Brown D, Leissinger C, Shapiro AD, Abshire TC, Manco-Johnson MJ; Joint Outcome Study Group Investigators.

Haemophilia. 2019 Sep;25(5):867-875. doi: 10.1111/hae.13778. Epub 2019 May 21.

PMID:
31115111
3.

Von Willebrand disease in the United States: perspective from the Zimmerman program.

Flood VH, Abshire TC, Christopherson PA, Friedman KD, Cox Gill J, Montgomery RR, Haberichter SL; Zimmerman Program Investigators.

Ann Blood. 2018 Jan;3. pii: 7. doi: 10.21037/aob.2017.12.05. Epub 2018 Jan 26.

4.
5.

Complications of haemophilia in babies (first two years of life): a report from the Centers for Disease Control and Prevention Universal Data Collection System.

Kulkarni R, Presley RJ, Lusher JM, Shapiro AD, Gill JC, Manco-Johnson M, Koerper MA, Abshire TC, DiMichele D, Hoots WK, Mathew P, Nugent DJ, Geraghty S, Evatt BL, Soucie JM.

Haemophilia. 2017 Mar;23(2):207-214. doi: 10.1111/hae.13081. Epub 2016 Nov 4.

6.

Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States.

Flood VH, Christopherson PA, Gill JC, Friedman KD, Haberichter SL, Bellissimo DB, Udani RA, Dasgupta M, Hoffmann RG, Ragni MV, Shapiro AD, Lusher JM, Lentz SR, Abshire TC, Leissinger C, Hoots WK, Manco-Johnson MJ, Gruppo RA, Boggio LN, Montgomery KT, Goodeve AC, James PD, Lillicrap D, Peake IR, Montgomery RR.

Blood. 2016 May 19;127(20):2481-8. doi: 10.1182/blood-2015-10-673681. Epub 2016 Feb 9.

7.

Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy: results from the von Willebrand Disease Prophylaxis Network.

Holm E, Abshire TC, Bowen J, Álvarez MT, Bolton-Maggs P, Carcao M, Federici AB, Gill JC, Halimeh S, Kempton C, Key NS, Kouides P, Lail A, Landorph A, Leebeek F, Makris M, Mannucci P, Mauser-Bunschoten EP, Nugent D, Valentino LA, Winikoff R, Berntorp E.

Blood Coagul Fibrinolysis. 2015 Jun;26(4):383-8. doi: 10.1097/MBC.0000000000000257.

PMID:
25688461
8.

Evaluation for bleeding disorders in suspected child abuse.

Anderst JD, Carpenter SL, Abshire TC; Section on Hematology/Oncology and Committee on Child Abuse and Neglect of the American Academy of Pediatrics.

Pediatrics. 2013 Apr;131(4):e1314-22. doi: 10.1542/peds.2013-0195. Epub 2013 Mar 25.

PMID:
23530182
9.

Evaluating for suspected child abuse: conditions that predispose to bleeding.

Carpenter SL, Abshire TC, Anderst JD; Section on Hematology/Oncology and Committee on Child Abuse and Neglect of the American Academy of Pediatrics.

Pediatrics. 2013 Apr;131(4):e1357-73. doi: 10.1542/peds.2013-0196. Epub 2013 Mar 25. Review.

PMID:
23530171
10.

No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation.

Flood VH, Friedman KD, Gill JC, Haberichter SL, Christopherson PA, Branchford BR, Hoffmann RG, Abshire TC, Dunn AL, Di Paola JA, Hoots WK, Brown DL, Leissinger C, Lusher JM, Ragni MV, Shapiro AD, Montgomery RR.

Blood. 2013 May 2;121(18):3742-4. doi: 10.1182/blood-2012-12-471672. Epub 2013 Mar 21.

11.

Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN).

Abshire TC, Federici AB, Alvárez MT, Bowen J, Carcao MD, Cox Gill J, Key NS, Kouides PA, Kurnik K, Lail AE, Leebeek FW, Makris M, Mannucci PM, Winikoff R, Berntorp E; VWD PN.

Haemophilia. 2013 Jan;19(1):76-81. doi: 10.1111/j.1365-2516.2012.02916.x. Epub 2012 Jul 23.

12.

Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A.

Kempton CL, Abshire TC, Deveras RA, Hoots WK, Gill JC, Kessler CM, Key NS, Konkle BA, Kuriakose P, Macfarlane DE, Bergman G.

Haemophilia. 2012 Sep;18(5):798-804. doi: 10.1111/j.1365-2516.2012.02789.x. Epub 2012 Apr 19.

PMID:
22512291
13.

VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population.

Bellissimo DB, Christopherson PA, Flood VH, Gill JC, Friedman KD, Haberichter SL, Shapiro AD, Abshire TC, Leissinger C, Hoots WK, Lusher JM, Ragni MV, Montgomery RR.

Blood. 2012 Mar 1;119(9):2135-40. doi: 10.1182/blood-2011-10-384610. Epub 2011 Dec 23.

14.

A community-based partnership to promote information infrastructure for bleeding disorders.

Aschman DJ, Abshire TC, Shapiro AD, Lusher JM, Forsberg AD, Kulkarni R.

Am J Prev Med. 2011 Dec;41(6 Suppl 4):S332-7. doi: 10.1016/j.amepre.2011.09.018.

PMID:
22099355
15.

In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study.

Kempton CL, Soucie JM, Miller CH, Hooper C, Escobar MA, Cohen AJ, Key NS, Thompson AR, Abshire TC.

J Thromb Haemost. 2010 Oct;8(10):2224-31. doi: 10.1111/j.1538-7836.2010.04013.x.

16.

Evaluation of factor VIII pharmacokinetics and anti-factor VIII antibodies in four boys with haemophilia A and a poor clinical response to factor VIII.

Kempton CL, Meeks SL, Donald Harvey R 3rd, Abshire TC.

Haemophilia. 2011 Jan;17(1):155-6. doi: 10.1111/j.1365-2516.2010.02345.x. No abstract available.

PMID:
20579112
17.

Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor.

Flood VH, Gill JC, Morateck PA, Christopherson PA, Friedman KD, Haberichter SL, Branchford BR, Hoffmann RG, Abshire TC, Di Paola JA, Hoots WK, Leissinger C, Lusher JM, Ragni MV, Shapiro AD, Montgomery RR.

Blood. 2010 Jul 15;116(2):280-6. doi: 10.1182/blood-2009-10-249102. Epub 2010 Mar 15.

18.

The "parallel-cohort RCT": Novel design aspects and application in the Kids-DOTT trial of pediatric venous thromboembolism.

Goldenberg NA, Tripputi M, Crowther M, Abshire TC, DiMichele D, Manco-Johnson MJ, Hiatt WR.

Contemp Clin Trials. 2010 Jan;31(1):131-3. doi: 10.1016/j.cct.2009.11.006. Epub 2009 Nov 24.

PMID:
19941974
19.

Inhibitors of factor VIII in black patients with hemophilia.

Viel KR, Ameri A, Abshire TC, Iyer RV, Watts RG, Lutcher C, Channell C, Cole SA, Fernstrom KM, Nakaya S, Kasper CK, Thompson AR, Almasy L, Howard TE.

N Engl J Med. 2009 Apr 16;360(16):1618-27. doi: 10.1056/NEJMoa075760. Erratum in: N Engl J Med. 2009 Jul 30;361(5):544.

20.

Abnormalities of prothrombin: a review of the pathophysiology, diagnosis, and treatment.

Meeks SL, Abshire TC.

Haemophilia. 2008 Nov;14(6):1159-63. doi: 10.1111/j.1365-2516.2008.01832.x. Review.

PMID:
19141155
21.

Diagnosis of type 1 VWD: can the clinical history trump laboratory findings?

Abshire TC.

Pediatr Blood Cancer. 2009 Jan;52(1):7-8. doi: 10.1002/pbc.21800. No abstract available.

PMID:
19006252
22.

One year follow-up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab.

Mueller BU, Bennett CM, Feldman HA, Bussel JB, Abshire TC, Moore TB, Sawaf H, Loh ML, Rogers ZR, Glader BE, McCarthy MC, Mahoney DH, Olson TA, Feig SA, Lorenzana AN, Mentzer WC, Buchanan GR, Neufeld EJ; Pediatric Rituximab/ITP Study Group; Glaser Pediatric Research Network.

Pediatr Blood Cancer. 2009 Feb;52(2):259-62. doi: 10.1002/pbc.21757.

23.

Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.

Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, Ingram JD, Manco-Johnson ML, Funk S, Jacobson L, Valentino LA, Hoots WK, Buchanan GR, DiMichele D, Recht M, Brown D, Leissinger C, Bleak S, Cohen A, Mathew P, Matsunaga A, Medeiros D, Nugent D, Thomas GA, Thompson AA, McRedmond K, Soucie JM, Austin H, Evatt BL.

N Engl J Med. 2007 Aug 9;357(6):535-44.

25.

Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates.

Kempton CL, Soucie JM, Abshire TC.

J Thromb Haemost. 2006 Dec;4(12):2576-81. Epub 2006 Sep 26. Erratum in: J Thromb Haemost. 2007 Mar;5(3):657.

26.

Prophylaxis and von Willebrand's disease (vWD).

Abshire TC.

Thromb Res. 2006;118 Suppl 1:S3-7. Epub 2006 Mar 31. Review.

PMID:
16580053
27.

Current issues in prophylactic therapy for persons with hemophilia.

Dunn AL, Abshire TC.

Acta Haematol. 2006;115(3-4):162-71. Review.

PMID:
16549891
28.

Clinical uses of plasma and plasma fractions: plasma-derived products for hemophilias A and B, and for von Willebrand disease.

Josephson CD, Abshire TC.

Best Pract Res Clin Haematol. 2006;19(1):35-49. Review.

PMID:
16377540
29.

Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura.

Bennett CM, Rogers ZR, Kinnamon DD, Bussel JB, Mahoney DH, Abshire TC, Sawaf H, Moore TB, Loh ML, Glader BE, McCarthy MC, Mueller BU, Olson TA, Lorenzana AN, Mentzer WC, Buchanan GR, Feldman HA, Neufeld EJ.

Blood. 2006 Apr 1;107(7):2639-42. Epub 2005 Dec 13.

30.

Leukemia and P32 radionuclide synovectomy for hemophilic arthropathy.

Dunn AL, Manco-Johnson M, Busch MT, Balark KL, Abshire TC.

J Thromb Haemost. 2005 Jul;3(7):1541-2. No abstract available.

31.

Recent advances in the management of the child who has hemophilia.

Dunn AL, Abshire TC.

Hematol Oncol Clin North Am. 2004 Dec;18(6):1249-76, viii. Review.

PMID:
15511615
32.

The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B.

Shapiro AD, Di Paola J, Cohen A, Pasi KJ, Heisel MA, Blanchette VS, Abshire TC, Hoots WK, Lusher JM, Negrier C, Rothschild C, Roth DA.

Blood. 2005 Jan 15;105(2):518-25. Epub 2004 Sep 21.

PMID:
15383463
33.

Arthroscopic synovectomy for hemophilic joint disease in a pediatric population.

Dunn AL, Busch MT, Wyly JB, Sullivan KM, Abshire TC.

J Pediatr Orthop. 2004 Jul-Aug;24(4):414-26.

PMID:
15205625
34.

IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life.

Bussel JB, Eldor A, Kelton JG, Varon D, Brenner B, Gillis S, Angiolillo A, Kulkarni R, Abshire TC, Kelleher J; IGIV-C in ITP Study Group.

Thromb Haemost. 2004 Apr;91(4):771-8.

PMID:
15045139
36.

An approach to the diagnosis and treatment of bleeding disorders in infants.

Abshire TC.

Int J Hematol. 2002 Aug;76 Suppl 2:265-70. Review.

PMID:
12430935
37.

Hepatitis C in adults and adolescents with hemophilia: a randomized, controlled trial of interferon alfa-2b and ribavirin.

Fried MW, Peter J, Hoots K, Gaglio PJ, Talbut D, Davis PC, Key NS, White GC, Lindblad L, Rickles FR, Abshire TC.

Hepatology. 2002 Oct;36(4 Pt 1):967-72.

PMID:
12297845
38.

Radionuclide synovectomy for hemophilic arthropathy: a comprehensive review of safety and efficacy and recommendation for a standardized treatment protocol.

Dunn AL, Busch MT, Wyly JB, Abshire TC.

Thromb Haemost. 2002 Mar;87(3):383-93. Review. No abstract available.

PMID:
11916068
40.

Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy--International Kogenate-FS Study Group.

Abshire TC, Brackmann HH, Scharrer I, Hoots K, Gazengel C, Powell JS, Gorina E, Kellermann E, Vosburgh E.

Thromb Haemost. 2000 Jun;83(6):811-6.

PMID:
10896230
41.

Incidence and prognostic significance of MDM2 oncoprotein overexpression in relapsed childhood acute lymphoblastic leukemia.

Zhou M, Gu L, Abshire TC, Homans A, Billett AL, Yeager AM, Findley HW.

Leukemia. 2000 Jan;14(1):61-7.

42.
44.

Coagulopathy in pediatric abusive head trauma.

Hymel KP, Abshire TC, Luckey DW, Jenny C.

Pediatrics. 1997 Mar;99(3):371-5.

PMID:
9041291
45.

Idarubicin and cytosine arabinoside reinduction therapy for children with multiple recurrent or refractory acute lymphoblastic leukemia: a Pediatric Oncology Group study.

Bernstein ML, Abshire TC, Pollock BH, Devine S, Toledano S, Steuber CP, Bowman WP, Buchanan GR.

J Pediatr Hematol Oncol. 1997 Jan-Feb;19(1):68-72.

PMID:
9065722
46.

The anemia of inflammation. A common cause of childhood anemia.

Abshire TC.

Pediatr Clin North Am. 1996 Jun;43(3):623-37. Review.

PMID:
8649902
47.

The prolonged thrombin time of nephrotic syndrome.

Abshire TC, Fink LK, Christian J, Hathaway WE.

J Pediatr Hematol Oncol. 1995 May;17(2):156-62.

PMID:
7749766
48.

Prevalence of von Willebrand disease in children: a multiethnic study.

Werner EJ, Broxson EH, Tucker EL, Giroux DS, Shults J, Abshire TC.

J Pediatr. 1993 Dec;123(6):893-8.

PMID:
8229521
49.

Dysfunctional protein C deficiency (type II). A report of 11 cases in 3 American families and review of the literature.

Berdeaux DH, Abshire TC, Marlar RA.

Am J Clin Pathol. 1993 Jun;99(6):677-86. Review.

PMID:
8322701
50.

Supplemental Content

Loading ...
Support Center